Milestone Pharmaceuticals Inc. - Common Shares (MIST)
1.5900
-0.1300 (-7.56%)
NASDAQ· Last Trade: May 14th, 11:00 AM EDT
Detailed Quote
Previous Close
1.720
Open
1.670
Bid
1.580
Ask
1.590
Day's Range
1.560 - 1.690
52 Week Range
1.000 - 3.060
Volume
1,605,528
Market Cap
84.83M
PE Ratio (TTM)
-1.939
EPS (TTM)
-0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,567,008
Chart
About Milestone Pharmaceuticals Inc. - Common Shares (MIST)
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular diseases, particularly those related to arrhythmias. The company's primary research centers around a new class of therapies aimed at providing effective and safe options for patients suffering from specific heart conditions. By leveraging advanced technology and scientific expertise, Milestone strives to address unmet medical needs and improve the quality of life for individuals affected by these disorders, while advancing its pipeline of potential medicines through rigorous clinical trials. Read More
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York.
Milestone Pharmaceuticals (NASDAQ:MIST) said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibr
Synergy CHC Corp. (NASDAQ: SNYR) continues to build momentum behind its functional beverage strategy, announcing new Direct Store Delivery (DSD) partnerships across Maine and Pennsylvania that expand retail distribution of FOCUSfactor® Focus + Energy RTD beverages and brain-health shots .
Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Milestone Pharmaceuticals beat Q3 earnings estimates, with a narrower loss. The stock rose as investors await the December 2025 FDA decision for its lead drug, CARDAMYST™.
Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.
FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support potential PSVT treatment launch.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.
